Issue № 24 | 2016 (2)
A pharmacoeconomic study of aflibercept versus ranibizumab in patients with diabetic macular edema in Russian health care system was conducted. The study included the cost-efficiency assessment of the mentioned drugs. The analysis revealed statistically significant advantages of aflibercept over ranibizumab in diabetic macular edema. The calculated cost-efficiency ratio was 39 165 RUB and 30 582 RUB for aflibercept, and 42 886 RUB and 33 825 RUB for ranibizumab in general population of patients and in subgroup with the 20/50 initial visual acuity or worse on Snellen chart, respectively. This suggests that aflibercept has pharmacoeconomic advantages because of its lower cost-efficiency ratio.
diabetic macular edema, diabetic retinopathy, pharmacoeconomics, cost-efficiency analysis, aflibercept, ranibizumab.
Protsenko M.V. Economic Analysis of Aflibercept in Patients with Diabetic Macular Edema. Medical Technologies. Assessment and Choice. 2016; 2(24): 67–71.